We recently developed a highly efficient automated enzyme-linked immunosorbent assay system for TFPI2 detection and determined the adequate cutoff level of serum TFPI2 to discriminate patients with CCC from other epithelial ovarian cancers and borderline tumors or benign ovarian lesions including endometriosis [13]. This evidence concerns the gene TFPI2 and endometriosis.